<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-127 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-127</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-127</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-3.html">extraction-schema-3</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of the prevalence, types, and mechanisms of EGFR mutations in lung cancer across different populations, especially East Asians versus others, including proposed genetic, environmental, or lifestyle explanations for ethnic differences.</div>
                <p><strong>Paper ID:</strong> paper-6033885</p>
                <p><strong>Paper Title:</strong> Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients</p>
                <p><strong>Paper Abstract:</strong> OBJECTIVE: Epidermal growth factor receptor is involved in the pathogenesis of non-small cell lung cancer and has recently emerged as an important target for molecular therapeutics. The KRAS oncogene also plays an important role in the development of lung cancer. The aim of this study was to evaluate the frequency of epidermal growth factor receptor and KRAS mutations in a population of Brazilian patients with non-small cell lung cancer. METHODS: A total of 207 specimens from Brazilian patients with non-small cell lung cancer were analyzed for activating epidermal growth factor receptor and KRAS somatic mutations, and their associations with clinicopathological characteristics (including age, gender, ethnicity, smoking habits, and histological subtype) were examined. RESULTS: We identified 63 cases (30.4%) with epidermal growth factor receptor mutations and 30 cases (14.6%) with KRAS mutations. The most frequent epidermal growth factor receptor mutation we detected was a deletion in exon 19 (60.3%, 38 patients), followed by an L858R amino acid substitution in exon 21 (27%, 17 patients). The most common types of KRAS mutations were found in codon 12. There were no significant differences in epidermal growth factor receptor or KRAS mutations by gender or primary versus metastatic lung cancer. There was a higher prevalence of KRAS mutations in the non-Asian patients. Epidermal growth factor receptor mutations were more prevalent in adenocarcinomas than in non-adenocarcinoma histological types. Being a non-smoker was significantly associated with the prevalence of epidermal growth factor receptor mutations, but the prevalence of KRAS mutations was significantly associated with smoking. CONCLUSIONS: This study is the first to examine the prevalence of epidermal growth factor receptor and KRAS mutations in a Brazilian population sample with non-small cell lung cancer.</p>
                <p><strong>Cost:</strong> 0.011</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e127.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e127.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of the prevalence, types, and mechanisms of EGFR mutations in lung cancer across different populations, especially East Asians versus others, including proposed genetic, environmental, or lifestyle explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR (Brazil study)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal growth factor receptor mutations in Brazilian NSCLC patients</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Observed prevalence, exon distribution, and clinicopathologic associations of somatic EGFR mutations in a multi-region Brazilian series of non-small cell lung cancer (NSCLC) patients (n=207) analyzed by PCR and direct sequencing.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>population_studied</strong></td>
                            <td>Brazilian NSCLC patients from all five geographic regions of Brazil (admixed population; 13 Asian-ancestry and 194 non-Asian reported), including adenocarcinomas and non-adenocarcinoma types</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td>207</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_prevalence</strong></td>
                            <td>63/207 = 30.4% overall. By exon among EGFR-mutant cases (n=63): exon 19 deletions 38/63 = 60.3% (38/207 = 18.4% overall), exon 21 L858R 17/63 = 27.0% (17/207 = 8.2% overall), exon 18 (codon 719) 5/63 = 7.9% (5/207 = 2.4% overall), exon 20 in-frame insertions 3/63 = 4.8% (3/207 = 1.4% overall), exon 21 L861Q 1/63 = 1.6% (1/207 = 0.5% overall).</td>
                        </tr>
                        <tr>
                            <td><strong>mutation_types</strong></td>
                            <td>Most frequent: exon 19 deletions (38 patients, 60.3% of EGFR mutants), L858R substitution in exon 21 (17 patients, 27.0%); less common: codon 719 point mutations in exon 18 (5 patients, 7.9%), exon 20 insertions (3 patients, 4.8%), L861Q in exon 21 (1 patient).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanisms</strong></td>
                            <td>Authors propose that the relatively high EGFR mutation frequency in this Brazilian sample (30.4%) compared with reported European rates (8-13%) may reflect Brazil's extensive multi-continental admixture (Amerindian, European, African, Asian) i.e., genetic ancestry rather than geographic/environmental exposures; additionally, lifestyle (smoking) is inversely associated with EGFR mutations (higher prevalence in never-smokers).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_mechanisms</strong></td>
                            <td>Observational associations: (1) EGFR mutations strongly associated with never-smoker status in this cohort (40/88 never-smokers mutated = 45.5% vs 14/74 smokers mutated = 18.9%), and (2) literature reports higher EGFR prevalence in East Asians and no consistent geographic clustering, supporting a genetic/ancestry component (cited prior studies). The study's Brazilian sample represents a highly admixed population, consistent with a genetic-ancestry explanation for an intermediate-to-high EGFR rate.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_mechanisms</strong></td>
                            <td>No direct genetic ancestry (genotyping/admixture) data were collected in the study to link observed mutation frequency to specific ancestral contributions; the Asian-ancestry subgroup in this dataset is small (n=13), limiting power to detect ethnic differences; authors note that lack of a geographic association in prior reports could also be interpreted differently and does not prove a purely genetic cause. Environmental explanations were not directly tested in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_implications</strong></td>
                            <td>EGFR-activating mutations (particularly exon 19 deletions and L858R) are predictive of response to EGFR tyrosine kinase inhibitors (TKIs); the paper reiterates literature reports of markedly better progression-free survival and high response rates (~81% in mutated patients in cited studies vs <10% in wild-type), supporting routine EGFR testing to guide TKI therapy. KRAS mutations (14.6% in this cohort) were mutually exclusive with EGFR and associated with smoking and resistance to EGFR-TKIs.</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Retrospective observational molecular prevalence study analyzing formalin-fixed paraffin-embedded (FFPE) tumor specimens referred for EGFR/KRAS testing; PCR amplification and direct Sanger sequencing (exons 18-21 of EGFR; exon 2 of KRAS), supplemented by real-time PCR allelic discrimination for KRAS.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Bacchi CE, Ciol H, Queiroga EM, Benine LC, Silva LH, Ojopi EB. Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients. Clinics. 2012;67(5):419-424. DOI: 10.6061/clinics/2012(05)03</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e127.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e127.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of the prevalence, types, and mechanisms of EGFR mutations in lung cancer across different populations, especially East Asians versus others, including proposed genetic, environmental, or lifestyle explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Ethnic variation (EGFR/KRAS)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Reported ethnic differences in EGFR and KRAS mutation prevalence in lung cancer (literature summary cited in paper)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Summary in the paper of published prevalence ranges and associations showing higher EGFR mutation frequencies in East Asians and never-smokers, and higher KRAS frequencies in Caucasians and smokers, with discussion of genetic versus environmental/lifestyle explanations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>population_studied</strong></td>
                            <td>East Asians, Europeans, African and white Americans, Caucasians (as reported across multiple previously published studies summarized in the paper)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_prevalence</strong></td>
                            <td>Cited literature ranges: East Asians ~27-60% (paper cites ranges 30-50% and 27-60% in different places), Europeans ~8-13%, African and white Americans ~12-16%; pooled compiled data from many studies showed distribution of EGFR mutations across exons among 569 mutations in 2880 patients: exon 19 ~48.2%, exon 21 ~42.7%, exon 20 ~3.7%, exon 18 ~3.2%.</td>
                        </tr>
                        <tr>
                            <td><strong>mutation_types</strong></td>
                            <td>Across cited studies, exon 19 deletions and exon 21 L858R are the most common activating EGFR mutations (~>80% combined of EGFR mutations), with smaller proportions in exon 18 and exon 20.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanisms</strong></td>
                            <td>Suggested explanations include (a) genetic ancestry / population-specific genetic predisposition (authors emphasize genetic rather than geographic/environmental explanations cited in prior literature), (b) lifestyle (smoking) differencesâ€”EGFR mutations enriched in never-smokers, KRAS associated with tobacco exposure, and (c) environmental carcinogens (e.g., tobacco polycyclic aromatic hydrocarbons) implicated in KRAS G>T transversions but not established for EGFR mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_mechanisms</strong></td>
                            <td>Evidence summarized includes consistent epidemiologic associations across multiple studies: higher EGFR mutation prevalence in East Asian cohorts and never-smokers; KRAS mutations more frequent in smokers and in Caucasian populations; molecular pattern evidence for tobacco causation of KRAS G->T transversions (leading to G12C) attributable to polycyclic aromatic hydrocarbons in tobacco smoke.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_mechanisms</strong></td>
                            <td>The paper notes no clear geographic associations in some studies and the lack of direct evidence tying environmental factors to EGFR prevalence, leading authors to favor a genetic/ancestry explanation; however, they also acknowledge limitations such as heterogeneous study designs in the literature and insufficient direct ancestry-genotype correlation studies, leaving room for alternative explanations.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_implications</strong></td>
                            <td>Because EGFR mutations are far more predictive of TKI responsiveness than clinical variables alone, the ethnic variation in mutation prevalence implies population-level differences in expected benefit from EGFR-TKIs; this motivates routine molecular testing rather than relying on ethnicity or smoking history alone for treatment decisions. KRAS mutations predict primary resistance to EGFR-TKIs and are more common in smokers/Caucasians.</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>This entity summarizes cross-study literature reports (meta-analyses, cohort studies) cited in the paper rather than a single study design.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td></td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib <em>(Rating: 2)</em></li>
                <li>EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib <em>(Rating: 2)</em></li>
                <li>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma <em>(Rating: 2)</em></li>
                <li>Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers <em>(Rating: 2)</em></li>
                <li>KRAS mutations and resistance to EGFR-TKIs treatment in patients with nonsmall cell lung cancer: a meta-analysis of 22 studies <em>(Rating: 2)</em></li>
                <li>Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer <em>(Rating: 1)</em></li>
                <li>The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>